Optiscan has been featured in The Sydney Morning Herald, The Age, The Brisbane Times, and Bulls N’ Bears following the launch of a major clinical trial at the Royal Melbourne Hospital evaluating the use of Optiscan’s InVue™ and InForm™ imaging systems in breast cancer surgery.

The article outlines how the trial will assess real-time imaging at the point of surgery to support more accurate tumour margin assessment and improve outcomes for patients undergoing lumpectomies. It also highlights the trial’s potential to accelerate regulatory submissions and support broader adoption of digital pathology in surgical workflows.

“We believe our innovative real-time microscopic imaging platform represents a genuine breakthrough in surgical cancer management by bringing live cellular imaging to the bedside. In the process, InVue will provide surgeons with digital tools to make confident, informed decisions about tumour clearance before patients leave the operating theatre,” said Dr. Camile Farah, Optiscan CEO.

“This highlights the critical need for innovative solutions that enable surgeons to assess tumour margins accurately and in real-time during the initial surgical procedure, improving outcomes for patients and reducing the burden on healthcare systems,” said Professor Bruce Mann, Director of Breast Cancer Services at the Royal Melbourne and Royal Women’s Hospitals.

The Sydney Morning Herald – Read the full article here
The Age – Read the full article here
The Brisbane Times – Read the full article here
Bulls N’ Bears – Read the full article here